S. 1414: Expedited Access to Biosimilars Act

S. 1414 is a federal bill in the 119th Congress. Before this bill, companies seeking approval for a biosimilar drug, which is a highly similar version of an existing complex biologic medication, were broadly required to conduct extensive clinical studies assessing comparative clinical efficacy,… See its sponsors, how members voted, and a plain-English breakdown on PolityLens.